41 reports

  • Risk Factors and Comorbidities for CKD
  • 4.1 BIBLIOGRAPHY

KIDNEY INTERNATIONAL SUPPLEMENTS; ##(##): ##-##.

  • Chronic Disease
  • Renal Disease
  • United Kingdom
  • United States
  • Forecast
  • Stages of chronic kidney disease
  • Aranesp late-phase trial data in anemia in chronic kidney disease

American Journal of Kidney Diseases, ##(##), ##-## < DOI> ##. ##/ ##-##(##)##-##< / DOI>.

  • Renal Disease
  • Japan
  • United States
  • Amgen Inc.
  • Roche Group
  • CHRONIC KIDNEY DISEASE (CKD)
  • UPDATES

GENE THERAPY GENE THERAPY COULD BE ONE OF THE PERFECT TREATMENT FOR RENAL DISEASES BECAUSE OF LIMITED THERAPEUTIC MOLECULE AND MINIMIZED SYSTEMIC EFFECT IN THE KIDNEY.

  • Renal Disease
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview End-stage kidney disease is the complete or almost complete failure of the kidneys to work.

  • Chronic Disease
  • Renal Disease
  • United States
  • World
  • Novartis AG
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview End-stage kidney disease is the complete or almost complete failure of the kidneys to work.

  • Renal Disease
  • Therapy
  • United States
  • World
  • CTI BioPharma Corp.
  • Polycystic Kidney Disease - Overview
  • Polycystic Kidney Disease - Dormant Projects

This treatment has been recommended to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage ## to ## at initiation of treatment with eviden

  • Renal Disease
  • Therapy
  • United States
  • Company
  • Product Initiative
  • TOP COMPANIES PARTICIPATING IN POLYCYSTIC KIDNEY DISEASE THERAPEUTICS CLINICAL TRIALS
  • POLYCYSTIC KIDNEY DISEASE THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY REGION (%), 2018*

POLYCYSTIC KIDNEY DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* POLYCYSTIC KIDNEY DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* POLYCYSTIC KIDNEY DISEASE THERAPEUTICS CLINICAL TRIALS, GL

  • Pharmaceutical
  • Renal Disease
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • Clinical Trial profile. 327 Trial Title
  • Clinical Trial profile. 285 Trial Title

CLINICAL TRIALS BY END POINT STATUS ANEMIA IN CHRONIC KIDNEY DISEASE (RENAL ANEMIA) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2018* ANEMIA IN CHRONIC KIDNEY DISEASE (RENAL ANEMIA) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2018* AN

  • Pharmaceutical
  • Renal Disease
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.

Kidney Disease Global Clinical Trials Review, H##, 2017 Table of Contents ## List of Tables ## List of Figures ## Report Guidance ## GlobalData Clinical Trials Report Coverage ## Clinical Trials by Region ## Clinical Trials and Average Enrollment by Country ## Top Five Countries Contributi

  • Chronic Disease
  • Clinical Trial
  • Drug Development
  • Renal Disease
  • World
  • END-STAGE KIDNEY DISEASE (END-STAGE RENAL DISEASE OR ESRD) THERAPEUTICS CLINICAL TRIALS, MIDDLE EAST AND AFRICA, TOP FIVE
  • END-STAGE KIDNEY DISEASE (END-STAGE RENAL DISEASE OR ESRD) THERAPEUTICS CLINICAL TRIALS, MIDDLE EAST AND AFRICA, TOP FIVE

END-STAGE KIDNEY DISEASE (END-STAGE RENAL DISEASE OR ESRD) THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* CLINICAL TRIALS BY PHASE IN E## COUNTRIES END-STAGE KIDNEY DISEASE (END-STAGE RENAL DISEASE OR ESRD) THERAPEUT

  • Chronic Disease
  • Clinical Trial
  • Renal Disease
  • Therapy
  • World
  • Polycystic Kidney Disease - Overview
  • Polycystic Kidney Disease - Therapeutics Development

It also conducts preclinical development programs in chronic kidney disease including diabetic nephropathy and polycystic kidney disease.

  • Renal Disease
  • Therapy
  • United States
  • Company Operations
  • Product Initiative
  • Stage of Development
  • Stage of Development

PRODUCTS IN PHASE II/ III AND I/ II ARE REFLECTED UNDER PHASE III AND PHASE II, RESPECTIVELY Phase III ## ## Phase II ## ## Phase I ## ## IND/ CTA Filed ## ## Preclinical ## ## Discovery ## ## Total ## ## Stage of Development Company Universities/ Institutes Source: GBI Research Angio

  • Molecular Diagnostics
  • Pathology
  • Pharmaceutical
  • Renal Disease
  • Therapy
  • DRUG FOR KIDNEY DISEASES - DRUG PROFILE
  • SMALL MOLECULES FOR CHRONIC KIDNEY DISEASE - DRUG PROFILE

Chronic kidney disease is the slow loss of kidney function over time.

  • Diabetes
  • Renal Disease
  • United States
  • Company
  • Product Initiative

The report focuses on drugs and therapies being evaluated for End-Stage Kidney Disease (end-stage renal disease or ESRD) treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Chronic Disease
  • Clinical Trial
  • Pathology
  • Renal Disease
  • DRUG FOR KIDNEY DISEASES - DRUG PROFILE
  • SMALL MOLECULES FOR CHRONIC KIDNEY DISEASE - DRUG PROFILE

Chronic kidney disease is the slow loss of kidney function over time.

  • Cell Therapy
  • Renal Disease
  • United States
  • Company
  • Product Initiative

Polycystic Kidney Disease Ongoing Global Clinical Trials Analysis and Outlook ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Key Findings, 2018 ##. ## Snapshot ##. ## Overview of Polycystic Kidney Disease Trials ## Clinical Trials Trends to 2022 ##.

  • Chronic Disease
  • Clinical Trial
  • Drug Development
  • Pathology
  • Renal Disease
  • Polycystic Kidney Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Top Companies Participating in Polycystic Kidney Disease Therapeutics Clinical Trials

Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials, E## Countries (%), 2016* Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials, E## Countries (%), 2016* Proportion of Polycystic Kidney

  • Drug Development
  • Genetic Disorder
  • Renal Disease
  • World
  • Product Initiative

Insights into Polycystic Kidney Disease Pipeline ##.

  • Chronic Disease
  • Renal Disease
  • World
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H1 2017

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development PIPELINE OVERVIEW Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H## 2017 Number of Produ

  • Pharmaceutical
  • Renal Disease
  • United States
  • World
  • CTI BioPharma Corp.

Insights into End Stage Renal Disease (ESRD) Pipeline ##.

  • Chronic Disease
  • Renal Disease
  • World
  • Renal Diseases, Global, Overall
  • Renal Diseases, Global, Percentage

Targeting the MCP-##/ CCR## System in Diabetic Kidney Disease.

  • Chronic Disease
  • Pathology
  • Renal Disease
  • Deals & Alliance
  • Galectin Therapeutics Inc.
  • Clinical Trial profile. 91 Trial Title
  • Clinical Trial profile. 258 Trial Title

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H##, 2016 Reference Code: GDHC##CTIDB Publication Date: SEP 2016 LIST OF FIGURES Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H##, 2016 outlines clinic

  • Blood Disease
  • Pharmaceutical
  • Renal Disease
  • World
  • Product Initiative

End-Stage Kidney Disease - Pipeline Insight, 2019 ##.

  • Renal Disease
  • Therapy

Polycystic Kidney Disease - Pipeline Insight, 2019 ##.

  • Renal Disease
  • Therapy
  • DRUG FOR KIDNEY DISEASES - DRUG PROFILE
  • SMALL MOLECULES FOR CHRONIC KIDNEY DISEASE - DRUG PROFILE

Chronic kidney disease is the slow loss of kidney function over time.

  • Chronic Disease
  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative

Given the high prevalence of kidney disease such as chronic and end-stage renal disease, the availability of resources for meeting the demand is still inadequate, indicating a strong presence of untapped opportunities in the global renal care market.

  • Chronic Disease
  • Healthcare
  • Renal Disease
  • Chile
  • Demand
  • 4.3.3 Low Awareness of Kidney Disease
  • 1.1 CHRONIC KIDNEY DISEASE (CKD)

End stage renal disease (ESRD) is the last stage of chronic kidney disease.

  • Renal Disease
  • World
  • Forecast
  • Market Size
  • Baxter International Inc.
  • MAY 23, 2017: CHEMOCENTRYX GRANTED EU ORPHAN DRUG DESIGNATION FOR AVACOPAN IN THE TREATMENT OF DEBILITATING KIDNEY DISEASE C3 GLOMERULOPATHY
  • MAR 22, 2017: CHEMOCENTRYX RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AVACOPAN IN THE TREATMENT OF DEBILITATING KIDNEY DISEASE C3 GLOMERULOPATHY

IgAN can lead to chronic kidney disease, kidney failure and End Stage Renal Disease (ESRD).

  • Renal Disease
  • United States
  • World
  • Product Initiative
  • ChemoCentryx, Inc.
  • MONOCLONAL ANTIBODIES TO INHIBIT ITGAM FOR CARDIOVASCULAR, IMMUNOLOGY AND KIDNEY DISEASES - DRUG PROFILE
  • SYNTHETIC PEPTIDES TO INHIBIT FACTOR D FOR GEOGRAPHIC ATROPHY, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND RENAL DISEASE - DRUG PROFILE

IgAN can lead to chronic kidney disease, kidney failure and End Stage Renal Disease (ESRD).

  • Autoimmune Disease
  • Pharmaceutical
  • Renal Disease
  • Type 2 Diabetes
  • ChemoCentryx, Inc.
  • Rising prevalence of kidney disease
  • RISING PREVALENCE OF KIDNEY DISEASES IS A MAJOR FACTOR DRIVING THE

U S Rising incidence of chronic kidney disease ##. ##. ## FIGURE ## CAUSES OF KIDNEY FAILURE IN THE US Increasing prevalence of hypertension TABLE ## High blood pressure (hypertension) is one of the major risk factors for chronic kidney

  • Clinical Chemistry
  • Diagnostics
  • In Vitro Diagnostics
  • Medical Device
  • Renal Disease